Sweden · Delayed Price · Currency is SEK Hansa Biopharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Imlifidase enables rapid desensitization for highly sensitized kidney transplant patients, showing strong clinical results and addressing a significant unmet need. The company monetized European rights for up to EUR 150 million to fund a robust U.S. launch and pipeline expansion, including next-gen therapies for autoimmune diseases.
-
IDEFIRIX was out-licensed for €110 million upfront plus a €5 million milestone, enabling broader European reach and significant non-dilutive funding. The deal extends cash runway, supports a robust U.S. launch, and reduces European costs, with key data and regulatory milestones ahead.
-
Q1 2026 saw a 48% revenue decline year-over-year amid major organizational changes, but financial runway was extended with a $30M convertible note and key clinical/regulatory milestones are expected in 2026. Early Q2 trends show improvement, with growth anticipated in H2.
-
Phase 3 data for imlifidase in kidney transplant will be presented in June, with strong trial results supporting regulatory progress and a focused U.S. launch strategy. Expansion opportunities include other organ transplants, gene therapy, and a next-gen protease for rare diseases.
-
A novel IgG-cleaving enzyme platform is advancing in kidney transplantation, GBS, and gene therapy, with strong clinical data, growing commercial traction in Europe, and a U.S. launch targeted for late 2026 pending regulatory milestones. U.S. KOLs and European payers show high enthusiasm, and operational improvements are underway.
Fiscal Year 2025
-
Q4 and full-year revenues surged, driven by strong European sales and strategic execution. Cash runway is secured into 2027 following a major equity raise, with U.S. launch preparations advancing and key regulatory milestones expected in 2026.
-
A novel IgG-cleaving enzyme platform targets highly sensitized kidney transplant patients and rare autoimmune diseases, with a BLA filing planned by year-end and potential U.S. approval by August next year. No late-stage competitors exist, and commercial rollout is well-prepared.
-
KOLs highlighted imlifidase's transformative impact for highly sensitized kidney transplant patients, citing robust phase III efficacy and safety data, rapid IgG reduction, and significant improvements in transplant access and outcomes. Rapid adoption and policy changes are anticipated.
-
Imlifidase enables kidney transplants for highly sensitized patients, with U.S. and EU phase 3 trials supporting regulatory filings and commercial growth. Key catalysts include anti-GBM data, BLA submission, and expanded gene therapy partnerships.
-
Q3 2025 saw lower European sales due to regional challenges, but annual growth remains strong and the U.S. market presents a major opportunity, supported by robust phase III data. Cash position is solid after recent equity raises, and 2026 is expected to bring improved performance.
-
The Confide S Phase III trial showed imlifidase significantly improved kidney function and reduced dialysis dependency in highly sensitized transplant patients, with a favorable safety profile. Plans are underway for FDA submission and a US launch, targeting a major unmet need in the transplant market.
-
The company is advancing its IgG-cleaving enzyme platform, with imminent Phase 3 readouts in kidney transplant and anti-GBM disease. US commercialization is expected to outpace Europe due to broader trial participation and operational improvements, while pipeline expansion in GBS and gene therapy continues.
-
Sales and revenue grew strongly in Q2 and H1 2025, driven by Idefirix expansion and new market access. Cash runway extended into Q2 2026 after capital raise and debt restructuring, with key Phase III trial readouts expected later in 2025.
-
Imlifidase demonstrated rapid and significant improvement in strength and disability for severe GBS patients, outperforming standard IVIG in a matched indirect comparison. The therapy was well tolerated, with a strong safety profile and potential to transform GBS care.
-
Q1 2025 saw 18% revenue growth and a 39% increase in product sales, driven by strong Idefirix uptake and expanded European reimbursement. Operating loss improved 71% year-over-year, and the company completed key clinical milestones while appointing a new CEO to guide strategic review.
-
A highly differentiated IgG-cleaving enzyme platform is advancing in transplantation, autoimmune, and gene therapy, with strong clinical results and significant commercial growth in Europe. Key phase III and gene therapy data readouts are expected in 2024–2025.
Fiscal Year 2024
-
2024 saw strong revenue and IDEFIRIX sales growth, expanded reimbursement, and pipeline progress, including positive GBS data and new gene therapy trials. Operating loss improved, and 2025 is expected to bring further growth as key studies complete and new markets open.
-
Phase II results in severe GBS showed imlifidase plus IVIG led to much faster recovery and higher rates of independent walking versus IVIG alone, with a strong safety profile. Comparative analysis with real-world data confirmed significant clinical benefit and supports advancing to phase III trials.
-
Record Idefirix sales and strong year-to-date growth were driven by expanded adoption and repeat use in key EU markets. Clinical pipeline advanced with pivotal trials on track for 2025 readouts, and positive data for HNSA-5487 supports further development in neuro autoimmune diseases.
-
HNSA-5487, a next-generation IgG cleaving enzyme, showed rapid and robust IgG reduction (>95%) with a favorable safety and immunogenicity profile in a phase I study, supporting repeat dosing. Initial clinical focus will be on severe autoimmune neurological diseases with high unmet need.
-
Q2 2024 saw strong Idefirix sales growth, expanded European market access, and full randomization of the pivotal U.S. ConfIdeS trial. Operating loss narrowed due to higher sales and cost controls, with cash runway extended into 2026.